Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 23 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 23 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 10 Jun 2017 Biomarkers information updated